To determine the relative effectiveness of moderate versus more aggressive lipid lowering,
and of low dose anticoagulation versus placebo, in delaying saphenous vein coronary bypass
graft atherosclerosis and preventing occlusion of saphenous grafts of patients with saphenous
vein coronary bypass grafts placed 1 to 11 years previously.
Phase:
Phase 3
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Cholestyramine Resin Dihydromevinolin L 647318 Lovastatin Warfarin